Don't Let Shkreli Hijack Pharma's Reputation
This article was originally published in Scrip
Executive Summary
This week Martin Shkreli and his devil-may-care attitude to price gouging has effectively taken the delicate hope for an informed public debate about how to balance society's need for medicines and its ability to pay with the R&D risks and costs and profit motive of the pharmaceutical industry, and smashed it to smithereens.